Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment.

Moore AE, Blake GM, Taylor KA, Rana AE, Wong M, Chen P, Fogelman I

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 May 2010Cited by 30 (Europe PMC)

PMID19929434DOI10.1359/jbmr.091108PepBankPUB-19929434

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialActivity measurement
In women with osteoporosis, whole-skeleton tracer plasma clearance increased by 22.3% after three months of teriparatide versus baseline.
In plain wordsIn women with osteoporosis, teriparatide increased whole-skeleton tracer clearance compared with baseline at the early assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWhole-skeleton plasma clearance at early assessment
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Median K(bone) increase
22.3%
3 months versus baseline
Source sentences
Summary
Median increases from baseline in whole-skeleton K(bone) were 22.3% (p = .004) and 33.7% (p = .002) at 3 and 18 months, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943401
02HumanNon-randomized trialActivity measurement
In women with osteoporosis, whole-skeleton tracer plasma clearance increased by 33.7% after 18 months of teriparatide versus baseline.
In plain wordsIn women with osteoporosis, teriparatide increased whole-skeleton tracer clearance compared with baseline at the late assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWhole-skeleton plasma clearance at late assessment
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Median K(bone) increase
33.7%
18 months versus baseline
Source sentences
Summary
Median increases from baseline in whole-skeleton K(bone) were 22.3% (p = .004) and 33.7% (p = .002) at 3 and 18 months, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943402
03HumanNon-randomized trialActivity measurement
In women with osteoporosis, regional bone tracer clearance (K(bone)) increased significantly versus baseline in all six skeletal subregions at 3 months and in all subregions except the pelvis at 18 months of teriparatide.
In plain wordsIn women with osteoporosis, bone tracer clearance rose in all six regions at 3 months and all but the pelvis at 18 months versus baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRegional bone tracer clearance (K(bone)) in six subregions
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Regional K(bone) values were increased significantly in all six subregions at 3 months and in all subregions except the pelvis at 18 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943403
04HumanNon-randomized trialActivity measurement
In women with osteoporosis, spine tracer clearance increased significantly versus baseline after three and 18 months of teriparatide.
In plain wordsIn women with osteoporosis, spine tracer clearance increased compared with baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine tracer clearance
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Regional K(bone) values were increased significantly in all six subregions at 3 months and in all subregions except the pelvis at 18 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The Patlak plot method was used to evaluate whole-skeleton (99m)Tc-MDP plasma clearance (K(bone)) and derive regional bone clearance for the calvarium, mandible, spine, pelvis, and upper and lower extremities using gamma camera counts.
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943405
05HumanNon-randomized trialActivity measurement
In women with osteoporosis, pelvis tracer clearance increased significantly versus baseline after three months of teriparatide.
In plain wordsIn women with osteoporosis, pelvic tracer clearance increased compared with baseline at the early teriparatide assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePelvis tracer clearance at early assessment
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Regional K(bone) values were increased significantly in all six subregions at 3 months and in all subregions except the pelvis at 18 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The Patlak plot method was used to evaluate whole-skeleton (99m)Tc-MDP plasma clearance (K(bone)) and derive regional bone clearance for the calvarium, mandible, spine, pelvis, and upper and lower extremities using gamma camera counts.
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943406
06HumanNon-randomized trialActivity measurement
In women with osteoporosis, pelvis tracer clearance did not increase significantly versus baseline after 18 months of teriparatide.
In plain wordsIn women with osteoporosis, pelvic tracer clearance did not significantly increase compared with baseline at the late teriparatide assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePelvis tracer clearance at late assessment
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Regional K(bone) values were increased significantly in all six subregions at 3 months and in all subregions except the pelvis at 18 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943407
07HumanNon-randomized trialActivity measurement
In women with osteoporosis, upper extremity tracer clearance increased significantly versus baseline after three and 18 months of teriparatide.
In plain wordsIn women with osteoporosis, arm tracer clearance increased compared with baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUpper extremity tracer clearance
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Regional K(bone) values were increased significantly in all six subregions at 3 months and in all subregions except the pelvis at 18 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The Patlak plot method was used to evaluate whole-skeleton (99m)Tc-MDP plasma clearance (K(bone)) and derive regional bone clearance for the calvarium, mandible, spine, pelvis, and upper and lower extremities using gamma camera counts.
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943408
08HumanNon-randomized trialActivity measurement
In women with osteoporosis, lower extremity tracer clearance increased significantly versus baseline after three and 18 months of teriparatide.
In plain wordsIn women with osteoporosis, leg tracer clearance increased compared with baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLower extremity tracer clearance
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Regional K(bone) values were increased significantly in all six subregions at 3 months and in all subregions except the pelvis at 18 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The Patlak plot method was used to evaluate whole-skeleton (99m)Tc-MDP plasma clearance (K(bone)) and derive regional bone clearance for the calvarium, mandible, spine, pelvis, and upper and lower extremities using gamma camera counts.
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943409
09HumanNon-randomized trialActivity measurement
In women with osteoporosis, bone turnover markers increased significantly versus baseline after three and 18 months of teriparatide.
In plain wordsIn women with osteoporosis, bone turnover markers increased compared with baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone turnover markers
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Bone markers were increased significantly from baseline at 3 and 18 months and correlated significantly with whole-skeleton K(bone).
1 context sentence(design, population, supporting numbers)
Summary · context
Changes in bone plasma clearance using technetium-99m methylene diphosphonate ((99m)Tc-MDP) were quantified and correlated with changes in bone turnover markers in 10 postmenopausal women with osteoporosis. Subjects underwent bone scintigraphy at baseline and 3 and 18 months after initiating TPTD 20…
Report a problemFND-1992943410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00259298

Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

Eli Lilly and Companyn = 12Nov 2005 to Jul 2009

Osteoporosis

Trial page ClinicalTrials.govUpdated 11 Aug 2010

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.